Anaptysbio (ANAB) Accumulated Expenses (2016 - 2026)

Anaptysbio's Accumulated Expenses history runs 11 years deep, the most recent figure standing at $32.1 million for Q1 2026.

• Quarterly Accumulated Expenses fell 10.81% year-over-year to $32.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.1 million (down 10.81% YoY) and the FY2025 annual result came in at $32.7 million, down 17.28% from the prior year.
• Accumulated Expenses was $32.1 million for Q1 2026 at Anaptysbio, down from $32.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $39.5 million in Q4 2024 and bottomed at $15.8 million in Q1 2022.
• A 5-year average of $29.4 million and a median of $31.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 110.39% — and 2025, when it decreased 17.28%.
• Anaptysbio's Accumulated Expenses stood at $21.6 million in 2022, then soared by 43.15% to $31.0 million in 2023, then climbed by 27.56% to $39.5 million in 2024, then dropped by 17.28% to $32.7 million in 2025, then slipped by 1.86% to $32.1 million in 2026.
• Business Quant data shows ANAB's Accumulated Expenses at $32.1 million in Q1 2026, $32.7 million in Q4 2025, and $33.2 million in Q3 2025.